Zoetis Inc. (NYSE:ZTS) Given Consensus Recommendation of “Buy” by Brokerages

Zoetis Inc. (NYSE:ZTSGet Free Report) has been assigned an average rating of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat reports. Eight analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $223.78.

A number of brokerages have recently weighed in on ZTS. Jefferies Financial Group reissued a “buy” rating and set a $230.00 price target on shares of Zoetis in a research report on Tuesday, December 19th. The Goldman Sachs Group lifted their price target on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 1st. Stifel Nicolaus raised their price objective on shares of Zoetis from $195.00 to $215.00 and gave the stock a “buy” rating in a report on Friday, January 12th. Finally, Piper Sandler raised their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, November 6th.

View Our Latest Research Report on Zoetis

Zoetis Trading Up 0.6 %

Shares of NYSE ZTS opened at $190.17 on Tuesday. The company’s fifty day moving average is $191.25 and its 200-day moving average is $182.76. The stock has a market cap of $87.31 billion, a price-to-earnings ratio of 38.65, a P/E/G ratio of 2.77 and a beta of 0.88. Zoetis has a twelve month low of $151.03 and a twelve month high of $201.92. The company has a quick ratio of 2.16, a current ratio of 3.87 and a debt-to-equity ratio of 1.29.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 1st. Shareholders of record on Friday, January 19th will be paid a $0.432 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.38. This represents a $1.73 annualized dividend and a yield of 0.91%. The ex-dividend date is Thursday, January 18th. Zoetis’s payout ratio is presently 35.16%.

Insider Buying and Selling at Zoetis

In other Zoetis news, CEO Kristin C. Peck sold 13,000 shares of Zoetis stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $176.84, for a total value of $2,298,920.00. Following the sale, the chief executive officer now directly owns 56,843 shares in the company, valued at approximately $10,052,116.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $177.46, for a total transaction of $163,795.58. Following the transaction, the executive vice president now directly owns 22,665 shares in the company, valued at approximately $4,022,130.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kristin C. Peck sold 13,000 shares of the business’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $176.84, for a total transaction of $2,298,920.00. Following the transaction, the chief executive officer now owns 56,843 shares in the company, valued at $10,052,116.12. The disclosure for this sale can be found here. In the last three months, insiders have sold 17,346 shares of company stock worth $3,139,405. Insiders own 0.15% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. BOS Asset Management LLC increased its stake in shares of Zoetis by 3.2% during the 2nd quarter. BOS Asset Management LLC now owns 1,684 shares of the company’s stock worth $290,000 after purchasing an additional 53 shares during the last quarter. Enterprise Financial Services Corp increased its stake in shares of Zoetis by 2.3% during the 1st quarter. Enterprise Financial Services Corp now owns 2,446 shares of the company’s stock worth $407,000 after purchasing an additional 55 shares during the last quarter. Catalyst Financial Partners LLC increased its stake in shares of Zoetis by 3.4% during the 2nd quarter. Catalyst Financial Partners LLC now owns 1,700 shares of the company’s stock worth $293,000 after purchasing an additional 56 shares during the last quarter. CreativeOne Wealth LLC increased its stake in shares of Zoetis by 0.4% during the 2nd quarter. CreativeOne Wealth LLC now owns 12,833 shares of the company’s stock worth $2,210,000 after purchasing an additional 57 shares during the last quarter. Finally, MJP Associates Inc. ADV boosted its holdings in shares of Zoetis by 4.8% during the 3rd quarter. MJP Associates Inc. ADV now owns 1,275 shares of the company’s stock worth $222,000 after buying an additional 58 shares during the period. 89.47% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

(Get Free Report

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Further Reading

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.